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A b s t r a c t  
Sitagliptin phosphate when used alone is an oral anti hyperglycemic drug of the dipeptidyl 
peptidase-4 (DPP-4) inhibitor class. It is available as tablets under trade name JANUVIA. Metformin 
hydrochloride is used alone in the form of biguanide anti hyperglycemic agent for treating non-
insulin-dependent diabetes mellitus (NIDDM) and is available as both conventional and sustained 
release tablets. The objective of the present study was to develop a trilayered tablet of immediate 
release Sitagliptin phosphate layer and sustained release Metformin Hydrochloride layer. Apart from 
the aesthetic appeal this trilayered tablet is expected to improve glucose tolerance in patients with 
the type 2 diabetes by lowering both basal and postprandial plasma glucose, reducing the dose, 
reducing frequency of administration and dose related gastrointestinal side effects of metformin and 
improve its bioavailability thus improving the patient compliance. Metformin Hydrochloride has biological 
half-life of nearly 6 hours. An attempt was made to sustain its release by using two different 
polymers in two layers. Preformulation studies including drug excipient compatibility studies were 
conducted for both drugs. Different formulations of sustained release Metformin HCl tablets were 
prepared by using a combination of hydrophilic polymers like HPMC K100, HPMC K4M, HPMC K15 
M, pH sensitive polymer Carbopol 971P, retarding polymer Ethyl cellulose and Low substituted 
hydroxy propyl cellulose. Sitagliptin immediate release formulations were prepared using cross 
povidone, croscarmellose sodium and sodium starch glycolate as super disintegrants. The tablets 
were evaluated for all physico chemical parameters like angle of repose, bulk density, tapped 
density, Hausners ratio and carrÊs index. Based on the invitro dissolution data the formulations SF6, 
MF9 and MF8 were found to be the optimized formulations for Sitagliptin phosphate and Metformin 
Hydrochloride formulations respectively. Trilayered tablets were prepared by first preparing 
Metformin HCl layers namely MF3 and MF8 using lesser compression force. The final compression 
was made by placing Sitagliptin IR layer (SF6) on the Metformin layers with final hardness of 6.5 kg 
and evaluated. The IR layer of Sitagliptin phosphate layer disintegrated in 54.67 sec from the 
trilayered tablet. In vitro dissolution studies of Trilayered tablet were performed in USP type II 
apparatus. The cumulative % drug release of Sitagliptin phosphate SF6 was found to be 99.65% at 
30 min and Metformin HCl MF3 and MF8 was found to be 98.72 % at 12 hrs. From the study it is 
found that the formulations made from MF3 and MF8 combination of HPMC K15M and HPMC K4M 
polymers and SF6 Sodium starch glycolate used as super disintegrant was found to show optimum 
properties of required drug release.  
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Introduction 
Diabetes mellitus is a chronic metabolic disorder characterized by 
a high blood glucose concentration (hyperglycemia) caused by 
insulin deficiency and it is often combined with insulin resistance. 
Non-insulin dependent diabetes mellitus represents a 
heterogenous group comprising mild form of diabetes that occurs 
predominantly in adults. 
Sitagliptin phosphate (DPP-IV inhibitor) is an oral hypoglycemic 
agent commonly prescribed drug for the treatment of patients with 
type II diabetes mellitus [1]. Metformin hydrochloride is used alone 
in the form of biguanide anti hyperglycemic agent for treating non-
insulin-dependent diabetes mellitus [2]. The usual dosage for 
Metformin is 250ă500 mg 3-4 times daily, up to a 2.5 g/day. The 
absolute bioavailability of Metformin hydrochloride is 50ă60% and 
has biological half-life of 6.2 hrs. Frequent dosing schedule leading 
to high GI side effects and high daily dose makes its use 
uncommon. Hence there is a need to formulate SR Metformin 
tablets to prolong its duration of action and to reduce total dose of 
drug administered as well as the incidence of adverse side effects. 
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The combination of a DPP-4 Inhibitor with Metformin allows a 
broad and complementary spectrum of anti diabetic actions. This 
combination does not increase the risk of hypoglycemia, does not 
promote weight gain, and does not cause adverse effect caused by 
various other oral anti diabetic combinations. Both the drugs have 
a complimentary and possibly additive effect on glycemic control 
and reduced glycosylated heamoglobin [3]. 
Multilayer tablets are gaining importance in oral sustained drug 
delivery. They consist of an active matrix core and one or more 
layers applied during tableting which may act as barriers and 
regulate drug release. This is a best way of combination therapy for 
treating chronic diseases. These tablets may be designed for 
different drug release profiles, one layer for the immediate release 
of the drug and second layer for extended release and third layer 
for sustained release of the drug thus maintaining a prolonged 
blood level. Layers may be colored differently to identify the 
product. 
The objective of the present study was to develop a trilayered 
tablet of immediate release Sitagliptin phosphate layer and 
sustained release Metformin Hydrochloride layers. The formulation 
and evaluation of trilayered tablets are discussed. The results 
indicate that the optimized trilayered tablet formulation can be 
successfully used for treatment of diabetes in chronic patients. 
Material and Methods  
Materials 
Metformin hydrochloride was a kind gift from Gland pharma, Hyd, 
India. Sitagliptin phosphate was a gift sample provided by Matrix 
Labs, Hyderabad. HPMC K100, HPMC K4M, HPMC K15M, low 
substituted hydroxy propyl cellulose, Ethyl cellulose, Carbopol, 
Microcrystalline cellulose, Starch, Croscarmellose sodium, Sodium 
starch glycolate, Crospovidone, Sodium bi carbonate, Magnesium 
stearate, Talc were purchased from S.D Fine Chemicals, Mumbai. 
Methods 
Preparation of Trilayered tablets 
Trilayered tablets of Metformin HCl and Sitagliptin Phosphate were 
developed in three stages.  
Stage-1: Preparation and Optimization of Immediate release layer 
by wet granulation method. 
Stage-2: Preparation and Optimization of Sustained release layers 
I and II by wet granulation technique. 
Stage-3: Compression of Optimized IR layer and SR layers to form 
Trilayered tablet. 
Drug Excipient Compatibility  
The compatibility of drugs with their respective excipients was 
studied by FT-IR spectroscopy.  Scanning was performed at a 
speed of 2 mm/sec with resolution of 4 cm-1 over the region 4000-
400 cm-1. The scans were evaluated for presence of principle 
peaks of drug, shifting and masking of drug peaks and appearance 
of new peaks due to polymer interaction.   
Formulation of Sitagliptin phosphate immediate release 
layer blend of Trilayered tablet 
Sitagliptin phosphate immediate release layer was prepared by wet 
granulation method using varying concentrations of different super 
disintegrants.  
Wet Granulation Technique: It involves many steps such as  
1) Sifting: Weighed quantities of Sitagliptin phosphate, SSG, 
Crospovidone, Cross carmellose sodium and Micro crystalline 
cellulose, were sifted through sieve # 44. 
2) Binder preparation: Starch was dissolved in purified hot water.  
3) Dry mixing: The above sieved materials were weighed and 
mixed thoroughly for 15min. 
4) Granulation: Granules were prepared by adding Starch paste 
(1% solution) to dry blend and make it wet dough, and passed 
through sieve #18.  
5) Drying: The produced Sitagliptin phosphate granules were dried 
in hot air oven at 500C for 15 to 30min. 
6) Screening: Dried granules were passed through sieve #22 .  
7) Lubrication: Magnesium stearate and Talc were sifted through 
sieve #44 and added to dried granules and mixed for 2 minutes. 
8) Compression: The granules were compressed in Rotary Tablet 
Compression machine using 6mm deep concave punches plain on 
both sides at required pressure. [4] 
The various formulations (SF1 to SF6) of Sitagliptin phosphate 
immediate release layer are listed in Table 1 
 
Table 1 Composition of Sitagliptin phosphate immediate release blend using Super disintegrants 
Ingredients  SF1(mg) SF2(mg) SF3(mg) SF4(mg) SF5(mg) SF6(mg) 
Sitagliptin 64.5 64.5 64.5 64.5 64.5 64.5 
Cross povidone 10 15 --- --- --- --- 
Cross carmellose sodium --- --- 10 15 --- --- 
Sodium starch glycolate --- --- --- --- 10 15 
Microcrystalline cellulose 21.5 15.5 21.5 15.5 21.5 15.5 
Starch paste-5% q.s q.s q.s q.s q.s q.s 
Magnesium stearate  2.5 2.5 2.5 2.5 2.5 2.5 
Talc  2.5 2.5 2.5 2.5 2.5 2.5 
Avg weight of IR layer 100 100 100 100 100 100 
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Formulation of Metformin sustained release layers of 
Trilayered tablets with different concentrations of 
different polymers      
Metformin Hydrochloride sustained release layer containing 
(250mg dose) were formulated using varying concentrations of 
different polymers prepared by wet granulation technique. 
Wet Granulation Technique 
Weighed quantity of drug, polymer (L HPC, Carbopol 971P, Ethyl 
cellulose, HPMC Grades K100, K15M, and K4M) and micro 
crystalline cellulose were taken and mixed thoroughly. Granules 
were prepared using 1% PVP solution as binder and drying at 
400C for 1 hour. After drying, the granules were screened through 
sieve no 22. The blend was lubricated using magnesium stearate 
and talc was finally added and mixed thoroughly. The tablets were 
compressed in Rotary Tablet Compression machine using 10mm 
circular flat punches with a break line. 
The SR layer with 250mg of Metformin Hydrochloride was 
formulated using polymers. The quantitative composition of all the 
formulations MF1 to MF12 is shown in Table 2. [5] 
 
 
Table 2 Formulation of Metformin Hydrochloride (250mg dose) sustained release blend prepared using individual polymers 
 INGREDIENTS MF1 
(mg) 
MF2 
(mg) 
MF3
(mg) 
MF4
(mg)
MF5
(mg)
MF6
(mg)
MF7
(mg)
MF8
(mg)
MF9
(mg)
MF10 
(mg) 
MF11 
(mg) 
MF12
(mg) 
 Metformin   
 Hydrochloride 
250 250 250 250 250 250 250 250 250 250 250 250
 L HPC ---- ---- ---- ---- 70 77 ---- ---- ---- ----  --- --- 
 HPMC K 15M ---- ----  52.5  63 ---- ---- ---- ---- ----  ----  --- ----
 HPMC K100 63 70 ---- ---- ---- ---- ---- ---- ---- ---- ---- ----
 HPMC K 4M ---- ---- ---- ---- ---- ----  52.5  63 ---- ---- ---- ----
 Ethyl cellulose ---- ---- ---- ---- ---- ---- ---- ---- ---- ---- 70 77 
 Carbopol 971 ---- ---- ---- ---- ---- ---- ---- ---- 70 77 ---- ----
 Microcrystalline     
 cellulose 
32 25  42.5  32 25   18  42.5  32 25   18  25  18 
 PVP K-30 (1%) q.s q.s q.s q.s q.s q.s q.s q.s q.s q.s q.s q.s
 Magnesium    
 stearate 
2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5
  Talc 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5
Avg weight of SR 
layer 
350 350 350 350 350 350 350 350 350 350 350 350
 
Preparation of sustained release tablets 
The sustained release tablet was prepared using different polymers 
with varying concentrations in two layers to get aesthetic appeal. 
The SR layer I containing 250mg of Metformin Hydrochloride is 
placed in 10mm die compressed with low force. The second layer 
SR layer II was also placed into die and compressed with required 
pressure. The optimized formulation was compared to the 
marketed formulation (Glycomet SR®). The quantitative 
composition of all the formulations CMF1 to CMF6 is shown in 
Table 3. [6] 
Preparation of Trilayered tablets 
The granules of Sitagliptin phosphate immediate release layer 
containing average weight of 100mg was first placed in the 12mm 
die and compressed at low pressure. Then the SR I layer and SR II 
layer with average weight of 350mg each were placed into die and 
compressed at required pressure one upon the other using 12mm 
capsule shaped punches to form a Trilayered tablets. The different 
batches of Trilayered tablets were collected and stored in air tight 
containers. The quantitative composition of all the formulations TF1 
to TF6 is shown in Table 4. [7] 
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Table 3 Formulation of Metformin Hydrochloride (500mg dose) sustained release blend prepared using combination of polymers 
Ingredients CMF1(mg) CMF2(mg) CMF3(mg) CMF4(mg) CMF5(mg) CMF6(mg)
Sustained release layer I (SR I)
Metformin Hydrochloride 250 250 250 250 250 250
HPMC K 15M      ---     --- --- 52.5 52.5 52.5
LHPC --- --- 77 --- --- ---
HPMC K100 70 70 --- --- --- ---
PVP (1%) q.s q.s q.s q.s q.s q.s
Microcrystalline cellulose 25 25 18 42.5 42.5 42.5
Magnesium stearate 2.5 2.5 2.5 2.5 2.5 2.5
Talc 2.5 2.5 2.5 2.5 2.5 2.5
      Sustained release layer II (SR II)
Metformin Hydrochloride 250 250 250 250 250 250
Carbopol --- 77 --- 77 --- ---
Ethyl cellulose  --- --- --- --- --- 77
HPMC K4M 63 --- 63 --- 63 ---
PVP (1%) q.s q.s q.s q.s q.s q.s
Microcrystalline cellulose 32 18 32 18 32 18
Magnesium stearate 2.5 2.5 2.5 2.5 2.5 2.5
Talc 2.5 2.5 2.5 2.5 2.5 2.5
Average weight of SR layers 700 700 700 700 700 700
Preparation of Standard graph of Sitagliptin phosphate 
and Metformin Hydrochloride 
Calibration curve of Sitagliptin Phosphate was constructed by 
measuring the absorbance of different concentrations of drug in 0.1 
N HCl at 267 nm. Calibration curve of Metformin Hydrochloride was 
constructed by measuring the absorbance of different 
concentrations of drug in 0.1 N HCl and in pH 6.8 phosphate buffer 
at 231 nm. A graph was plotted by taking concentration on X axis 
and absorbance on Y axis.  
Physical characterization 
Metformin SR granules and Sitagliptin phosphate IR granules were 
prepared by wet granulation technique. The flow properties of the 
granules were evaluated by measuring Angle of repose, Bulk 
density, Tapped density, CarrÊs index, HausnerÊs ratio etc. using 
standard methods as per Indian pharmacopoeia. [8] 
 
 
Both Sitagliptin phosphate immediate release tablets and 
Metformin Hydrochloride sustained release tablets were evaluated 
for post compression parameters like hardness, weight variation, 
friability, drug content uniformity and in vitro dissolution study. The 
Optimized formulations were selected and their percentage drug 
release was compared with that of marketed tablets (Januvia®and 
Glycomet SR®). [9] 
Evaluation of Trilayered tablets 
All the post compression parameters like thickness, hardness, 
weight variation, friability, content uniformity of tablets containing 
both the drugs were measured.  
Invitro dissolution study  
The dissolution study of tri layered tablets was performed over a 12 
hr period using USP type II (paddle) Dissolution Testing Apparatus 
(Electro lab) Model. 900ml of 0.1N HCl was used as dissolution 
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Table 4-Composition of different Trilayered Tablets (TLT) 
 
 
 
IR 
L 
A 
Y 
E 
R 
 
INGREDIENTS 
TF-1  
(SF6+CF
1) 
TF-2
(SF6+C
F2) 
TF-3
(SF6+C
F3) 
TF-4
(SF6+C
F4) 
TF-5 
(SF6+C
F5) 
TF-6 
(SF6+C
F6) 
Sitagliptin Phosphate 64.5 64.5 64.5 64.5 64.5 64.5 
Sodium starch glycolate 10 10 10 10 10 10 
Microcrystalline cellulose 21.5 21.5 21.5 21.5 21.5 21.5 
Starch paste (5%) q.s q.s q.s q.s q.s q.s 
Magnesium stearate 2.5 2.5 2.5 2.5 2.5 2.5 
Talc 2.5 2.5 2.5 2.5 2.5 2.5 
Colour (poncaeu supra 
pink) 
q.s q.s q.s q.s q.s q.s 
SR 
L 
A 
Y 
E 
R 
1 
Metformin Hydrochloride 250 250 250 250 250 250 
HPMC K 15M      ---      --- --- 52.5 52.5 52.5 
LHPC --- --- 77 --- --- --- 
HPMC K100 70 70 --- --- --- --- 
PVP (1%) q.s q.s q.s q.s q.s q.s 
Microcrystalline cellulose 25 25 18 42.5 42.5 42.5 
Magnesium stearate 2.5 2.5 2.5 2.5 2.5 2.5 
Talc 2.5 2.5 2.5 2.5 2.5 2.5 
SR 
L 
A 
Y 
E 
R 
2 
Metformin Hydrochloride 250 250 250 250 250 250 
Carbopol --- 77 --- 77 --- --- 
Ethyl cellulose  --- --- --- --- --- 77 
HPMC K4M 63 --- 63 --- 63 --- 
PVP (1%) q.s q.s q.s q.s q.s q.s 
Microcrystalline cellulose 32 18 32 18 32 18 
Magnesium stearate 2.5 2.5 2.5 2.5 2.5 2.5 
Talc 2.5 2.5 2.5 2.5 2.5 2.5 
Colour(Sunset yellow) q.s q.s q.s q.s q.s q.s 
 Avg weight of Trilayered tablet  800mg 800mg 800mg 800mg 800mg 800mg 
 
medium agitated at 100 RPM, at temperature of 37μ 0.50C. 10 ml 
samples were withdrawn at 5,10,15,20,30,40,60 min for 1 hr to 
estimate the release of Sitagliptin phosphate, and at 1, 2, 4, 6, 8, 
10, 12 hrs for estimating Metformin release. Same volume of 
dissolution medium was replaced at every time interval. Samples 
were filtered by Whatman filter paper no. 41. The samples were  
analyzed for Sitagliptin phosphate and Metformin HCl by UV 
Spectrophotometry at their respective λ max values 267 nm and  
 
 
231 nm. The samples collected for first hour were analyzed for 
Sitagliptin content at 267 nm. The samples collected for 1 - 12 hrs 
were analyzed for the release of Metformin HCl at 231 nm. From in 
vitro dissolution study, the percentage drug release of both the 
drugs was compared with their respective marketed tablets 
(Januvia for Sitagliptin phosphate and Glycomet SR for Metformin 
Hydrochloride). [10] 
Stability studies 
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Stability studies were performed for optimized formulations at 40oC 
at 75% RH for 3 months and analyzed for their physical 
parameters, drug content and in vitro drug release studies at every 
one month intervals.  
Preparation of tablets for animal studies 
The tablets of average weight 50mg using 4mm deep concave 
punches plain on both sides were prepared for animal studies. 
In-vivo pharmacodynamic study 
Pharmacodynamic studies were conducted in male wistar rats 
weighing 200-250gm. Diabetes was induced at a previously 
standardized dose of 45mg/kg Streptozotocin. The animals were 
divided into 4 groups. Each group comprised of 3 rats 
(n=3).GROUP I (Control):  Untreated healthy rats. 
GROUP II (Diabetic control):  Untreated diabetic rats. 
GROUP III (Standard): Treated rats with Reference (Marketed 
tablet). 
GROUP IV (Test): Treated rats with optimized test formulation. 
After the administration through the oral feeding needle, blood was 
collected from the retro-orbital plexus using a capillary needle at 0, 
1, 2, 4, 5, 6, 8, 10 and 12hrs after oral administration. The blood 
glucose levels were determined by glucometer (Contour TS). [11] 
Results and discussions 
Calibration curve 
Calibration curve of both drugs were plotted by measuring 
absorbance at their respective absorption maxima with 0.1N HCl 
and Metformin HCl alone with 6.8 pH buffer as solvent. Both the 
drugs obeyed Beer-LambertÊs law by giving good correlation 
coefficient.  
FT-IR study of immediate release layer 
From the spectra obtained in Figures 1 and 2 it was observed that 
characteristic peaks appear with identical or with minor differences. 
There is no change in shift of major peaks of drug (C=O str, C=N 
str ,C-F str, NH2 10 amine (N-H)) was observed. From peaks it was 
evident that there was no chemical interaction between the drug 
and the superdisintegrant. 
 
 
 
 
Figure 1: FT-IR spectrum of pure Sitagliptin phosphate 
 
Figure 2: FT-IR spectrum of Sitagliptin phosphate with SSG 
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FT-IR study of sustained release layer 
From the spectra obtained in Figures 3 and 4 it was observed that 
characteristic peaks appear with identical or with minor differences. 
There is no change in shift of major peaks of drug (C-N str, C=N 
str, C-H str, NH2 10 amine (N-H) and N-H (20 amine) was observed. 
From peaks it was evident that there was no chemical interaction 
between the drug and the polymer 
 
 
                                Figure 3: FT-IR spectrum of pure Metformin HCl 
 
 
              Figure 4: FT-IR spectrum of Metformin HCl with HPMC K15M and HPMC K 4M 
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Preformulation studies 
The Sitagliptin phosphate and Metformin Hydrochloride granules 
were prepared by wet granulation method. The prepared granules 
of different batches were evaluated for their angle of repose, bulk  
density; tapped density, compressibility index and HausnerÊs ratio 
are reported in the Table 5. 
 
Table 5 Pre compression parameters of Sitagliptin phosphate 
immediate release granules and Metformin hydrochloride 
Sustained release layer I and II granules 
Formulations Bulk 
density 
Tapped  
density 
Angle 
of 
repose 
HausnerÊs
ratio 
CarrÊs
index 
SF1 0.296 0.34 28.52 1.16 17.7
SF2 0.38 0.44 26.5 1.15 13.6
SF3 0.31 0.35 29.60 1.13 11.5
SF4 0.353 0.399 27.51 1.13 10.4
SF5 0.43 0.487 23.4 1.12 9.1
SF6 0.39 0.427 29.74 1.10 10.9
Sustained release layer I 
MF1 0.356 0.416 31.1 1.17 14.4
MF2 0.425 0.458 28.8 1.08 7.2
MF3 0.412 0.461 24.2 1.12 10.6
MF4 0.359 0.394 23.7 1.10 8.8
MF5 0.426 0.455 25.7 1.07 6.6
MF6 0.394 0.453 27.9 1.15 13.02
      Sustained release layer II 
MF7 0.370 0.392 23.7 1.06 5.6
MF8 0.381 0.422 27.2 1.11 9.7
MF9 0.365 0.405 25.4 1.11 9.8
MF10 0.422 0.476 26.3 1.13 11.3
MF11 0.368 0.441 23.2 1.2 16.5
MF12 0.416 0.465 26.9 1.12 10.5
 
The bulk densities of the granules were found to be in the range of 
0.296 to 0.428 gm/ml. The angle of repose varied from 23.2 to 
29.7. The low values of angle of repose indicate the free flowing 
nature of the granules. The tapped densities ranged 0.34 to 0.487 
gm/ml and the CarrÊs indexes were in the range of 5.6 to 17.7. 
HausnerÊs ratio was found in the range of 1.06 to 1.18 and the 
values showed the low interparticle friction between the granules. 
 
 
 
Valuation parameters 
The physico-chemical characterization of the individually 
compressed tablets (immediate release layer, Sustained release 
layers containing 250mg dose, Combination of sustained release 
layers containing 500mg dose and optimized trilayered tablet) is 
shown in the Table 6, 7 and 8. The prepared tablets were 
evaluated for parameters such as Weight variation, Hardness, 
Friability, Thickness, drug content and in vitro dissolution profile. 
From the results reported in Tables 6, 7 and 8. Thickness was 
found to be in the range of 2.01 to 2.31mm, 5.14 to 5.81mm, 5.91 
to 6.20mm and 6.1μ0.04 for IR tablet, sustained release tablets 
containing 250mg dose, Combination of sustain release tablet and 
Optimized trilayered tablets respectively. Hardness of the tablets 
was in the range of 3.7 to 4.1 cm2 for IR tablet, 4.8 to 6.0 kg/cm2 
for SR tablets I and II individually, 5.9 to 6.3 for combination of 
sustain release tablets and 6.1μ0.4 for trilayered tablet which was 
sufficient for the handling of tablets throughout the shelf life. 
Percentage % friability was between 0.15ă1.87% and complies 
with pharmacopoeial limit. Weight variation was less than 5% 
which is a pharmacopoeia limit. Drug content of Metformin HCl 
found to be in the range of 85.3 %-99.54 %, was within the limit as 
per I.P and ICH guidelines and Drug content of Sitagliptin 
phosphate found to be in the range of 91.05 %-96.4 % was within 
the limit as per I.P and ICH guidelines.  
 
 
Figure 5: Trilayered tablets 
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Table 6 Evaluation parameters of Sitagliptin phosphate immediate release tablets and Metformin hydrochloride Sustained release tablets 
Formulations Weight-
Variation(n=20) 
Hardness
Kg/cm2 
(n=3) 
Thickness 
mm (n=3) 
Friability 
% (n=6) 
Drug 
Content(%) 
SF1 0.41 3.7  2.01 0.16 95.8 
SF2 0.26 4.7  2.13 0.05 96.4 
SF3 0.43 4.7  2.01 0.08 91.05 
SF4 0.57 4.5  2.31 0.18 93.23 
SF5 0.16 3.7  2.25 0.73 91.06 
SF6 0.11 4.7 2.14 0.06 93.05 
Sustained release I tablets 
MF1 1.05 6.0  5.64 1.10 91.08 
MF2 0.95 6.0  5.24 0.84 94.07 
MF3 0.92 6.1 5.46 0.98 97.54 
MF4 0.68 5.5 5.12 1.89 91.05 
MF5 0.16 6.2 5.41 0.96 92.04 
MF6 0.91 6.8 5.32 0.84 96.03 
Sustained release II tablets 
MF7 1.23 5.8 5.70 0.53 98.54 
MF8 0.64 6.2 5.81 1.14 94.05 
MF9 1.18 5.5  5.46 1.56 90.21 
MF10 1.44 6.0 5.64 1.04 96.70 
MF11 0.67 4.8  5.04 0.87 85.3 
MF12 0.94 5.9  5.15 1.13 91.64 
         `    *SF-Sitagliptin formulations. MF-Metformin formulations 
 
Table 7 Evaluation parameters of Metformin hydrochloride sustained release tablets (500mg dose) prepared using combination of polymers 
Formulations Hardness
 (Kg/m2) 
Friability
(%) 
Weight-
Variation  
Drug content 
(%) 
Thickness 
in (mm) 
CMF1 (MF3+MF8) 6.1 1.24 1.56 96.05 6.18 
CMF2(MF2+MF8) 5.9 1.05 0.52 92.05 6.20 
CMF3(MF3+MF12) 5.8 0.98 0.63 94.3 6.02 
CMF4(MF6+MF8) 6.3 0.86 0.89 91.05 5.91 
CMF5(MF2+MF10) 6.0 0.94 1.02 95.61 5.97 
CMF6 (MF3+MF10) 5.91 1.85 0.64 93.04 6.04 
                  *CF-Combination of Metformin formulations 
 
                  Table 8 Evaluation parameters of Optimized Trilayered tablets 
 
 
 
 
   
                       
                   
  *TF-Trilayered formulation 
 
 
  
Formulation Weight 
Variation
(n=20) 
Hardness
(n=3) 
Friability
(n=20) 
Thickness
(n=3) 
Drug content 
Sitagliptin
Phosphate 
Metformin 
HCl 
Trilayered tablet TF5 
  (SF6+MF3+MF8) 
 
0.53 6.3μ0.4 0.91μ0.5 6.1μ0.04 95.4μ1.3 
 
97.1μ1.05 
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In-vitro dissolution study 
The Cumulative % drug release of Sitagliptin phosphate IR tablet 
(SF1-SF6) formulated using different superdisintegrants (Cros 
Povidone, Cross Carmellose Sodium and Sodium Starch 
Glycolate) is graphically represented in Fig 6. From the dissolution 
studies it was concluded that disintegration activity decreases in 
the order of Cross Povidone < Cross Carmellose Sodium < Sodium 
Starch Glycolate i.e. from SF1 to SF6 disintegration time 
decreases and % cumulative drug release increases.  
The percentage drug released for the formulations SF1, SF3 and 
SF5 was found to be more than 95% after 45 minutes. The 
increase in concentration of superdisintegrants from 10mg to 15mg 
a gradual increase in drug release is observed. The percentage 
drug released formulations SF2, SF4 and SF6 was 98.76, 98.9 and 
99.65 respectively after 30 minutes. Therefore SF6 releasing 99.65 
% after 30 min was selected as optimized formulation and the drug 
release is almost similar to the marketed Sitagliptin tablets 
(Januvia) which is graphically represented in the Fig 7. 
 
Figure 6: Cumulative % drug release of Sitagliptin phosphate IR 
tablet formulated using different superdisintegrants 
 
 
 
Figure 7: Comparative In-vitro drug release comparison with 
marketed tablet (Januvia)50mg 
From the above comparative drug release profiles of tablets 
formulated with three super disintegrants, the formulation using 
SSG (SF6) has shown equivalent drug release profile of Januvia® 
50mg marketed tablets. Hence SF6 was selected as optimized 
formulation. 
Cumulative % drug release of Metformin Hydrochloride 
SR tablet containing 250mg dose 
The drug release rate of Metformin HCl was found to be influenced 
by the concentration of polymer used in the tablet. The influence of 
polymer concentration on drug release of formulations using 
different concentrations of L HPC, HPMC K 15M, HPMC K100, 
HPMC K4M, Ethyl cellulose and Carbopol is represented in Figures 
8, 9. With increased polymer concentration further decrease in the 
drug release was observed.  
From the Figures 8 and 9, it can be noted that MF1 and MF2 
formulations using LHPC as the release retarding polymer was 
able to sustain the release of the drug up to 12 hrs. The cumulative 
% drug release was found to decrease as the concentration of 
LHPC increased from 70 mg to 77mg. In case of MF1, 98.35% of 
drug release was observed in 10 hrs.  
Further trials were taken by taking HPMC K15M as the rate 
retarding polymer. Formulation MF4 with 18% of HPMC K15M 
achieved sustain release of more than 12hrs while MF3 with 15% 
of HPMC K15M also could sustain drug release up to 12hrs. From 
MF5 to MF6 as the concentration of HPMC K100 increases from 
18% to 20%, the drug release was found to decrease. In these 
formulations the drug release was not comparable to the marketed 
tablets at the end of 12 hrs. 
In case of formulations MF7 and MF8 high viscosity polymer 
HPMC K4M was taken in the range of 15%-18% concentration in 
which MF8 showed sustained drug release. Formulations MF9-
MF12 in which Carbopol 20% and Ethyl cellulose 22% were used 
could sustain drug release up to 12hrs. From these, formulations 
showing sustained drug release up to 12hrs were taken and 
combination of any two formulations was prepared in two layers to 
form bilayer sustained tablet and dissolution study was performed.  
 
 
Figure 8: Cumulative % drug release profiles of various 
formulations of Metformin SR I tablets 
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Figure 9: Cumulative % drug release profiles of various 
formulations of Metformin SR II tablets.  
Cumulative % drug release of Metformin Hydrochloride 
SR tablet containing 500mg dose 
Then further trials were taken to determine the effect of 
combination of polymers in two different layers. Dissolution data of 
formulations prepared by using combination of SR I and SR II 
layers containing different polymers with varying concentrations is 
graphically represented in Figure 10. Formulation CF1 containing 
20% of HPMC K 100 and 18% of HPMC K4M drug release is 
97.14% at 11hrs.  Formulation CF2 containing 20% of HPMC K 
100 and 22% of Carbopol drug release is 97.61% at 11hrs. 
Formulation CF3 containing 22% of LHPC and 18% of HPMC K4M 
drug release is 97.51% at 11hrs. Formulation CF4 containing 15% 
of HPMC K 15M and 22% of Carbopol drug release is 98.14% at 
12hrs. Formulation CF5 containing 15% of HPMC K 15M and 18% 
of HPMC K4M drug release is 98.72% at 12hrs. Formulation CF6 
containing 15% of HPMC K 15M and 22% of Ethyl cellulose drug 
release is 99.01% at 12hrs. Therefore CF5 releasing 99.01 % after 
12hrs was selected as Optimized formulation and the drug release 
was compared to the marketed Metformin HCl tablets (Glycomet 
SR) which is graphically represented in the Fig 11. 
 
 
Figure 10: Cumulative % drug release profiles of various 
formulations of combination of Metformin SR I and II tablets 
 
 
Figure 11: Comparative In-vitro drug release comparison of 
Metformin HCl sustained release tablet with marketed tablet 
From the above comparative drug release profile of tablets 
formulated with varying concentrations of different polymer, the 
formulation using HPMC K15M and K4M (MF3+MF8) has shown 
drug release comparable to the marketed Glycomet® SR 500mg 
tablets of Metformin HCl. Hence (MF3+MF8) was selected as 
optimized formulation of Metformin SR Layer. 
Drug release profile of Optimized trilayered tablet 
The Optimized formulations of IR layer (SF6) and SR layers 
(MF3+MF8) CF5 are compressed to form a Trilayered tablet (TF5). 
The dissolution study of Optimized trilayered tablet is performed 
and graphically represented in Figure 12. The IR layer 
disintegrated in 54.4 sec and the drug released is 99.65 in 30mins 
and from the SR layer drug released is 98.72 at 12hrs. 
As observed from the data, the % drug release of IR layer released 
in 30mins in 0.1 N HCl medium and % drug release of SR layers 
started to release at slow rate in 0.1N HCl medium for 2hrs and 
released completely for 10hrs in pH 6.8 buffer medium. 
The Optimized trilayered tablets, basing on this data were selected 
for further studies. 
 
 
Figure 12:  In vitro drug release of Optimized tri layered tablet 
Stability studies 
The stability studies were performed for Optimized trilayered tablet 
at elevated temperature (400C and 75%RH) for three months and 
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checked for physical characteristics and content uniformity. The 
stability data containing Hardness and Drug content is depicted in 
Table 9 
 
Table 9: Stability studies of Trilayered tablets at 400C and 75%RH 
Time interval Hardness Drug content 
Sitagliptin 
phosphate 
Metformin 
HCl 
After 1st month 6.1          95.03 96.51
After 2nd month 6.06         94.67 96.42 
After 3rd month 5.79         94.43 96.21 
 
As observed from the data, the formulation shows that there were 
no significant changes in the hardness and drug content. 
 
 
Figure 13: Graphical representation of blood glucose levels (mg/dl) 
after oral administration of Optimized formulation and Marketed 
formulation. 
 
 
 
In-vivo Pharmacodynamic study 
The tablets were prepared with average weight 40mg using 4mm 
punches plain both sides. The optimized tablet formulation and 
marketed formulation were administered to diabetes induced rats 
and the pharmacodynamics activity was compared and graphically 
represented in Figure 13. 
It is clear from the Figure 13 that the blood glucose levels in non- 
diabetic control group varied from 80 to 87 mg/dl. In diabetic 
control group, blood glucose levels varied from 307 to 314 mg/dl. 
From the data it is evident that the marketed tablets showed anti 
diabetic action up to 6 hrs and after 6 hrs increase in glucose levels 
was observed. However it is interesting to note that the optimized 
formulation MF3 and MF8 were able to achieve 12 hrs sustained 
antidiabetic action in the rats. The study indicates that TLT of 
Sitagliptin phosphate and Metformin HCl can be successfully for 
effective treatment of diabetes in chronic patients. 
Conclusion 
The trilayered tablets of Sitagliptin phosphate and Metformin 
Hydrochloride can be successfully formulated. Sitagliptin 
phosphate immediate release layer using different 
superdisintegrants and Metformin Hydrochloride sustained release 
layers is formulated using individual and combination of different 
polymers. All the evaluation parameters were found to be within 
specified Indian pharmacopoeia limits. The Sitagliptin layer gives 
the necessary immediate release dose and the two sustained 
release layers could prolong the release up to 12 hrs. Hence such 
tablets can be exploited for use in Diabetes treatment. 
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